

Special Issue

Contribution of Neural Stemness and Its Regulatory Networks to Tumorigenesis

Message from the Guest Editor

Cancer is a complex disease due to its genetic/phenotypic heterogeneities and the interactions between different components within the tumor microenvironment. It has been revealed that (1) cancer (tumorigenic) cells share regulatory networks and cellular properties with embryonic neural/neural stem cells; (2) the main characteristic of cancer (tumorigenic) cells is neural stemness, which represents general stemness and confers tumorigenicity and pluripotency to cancer cells; (3) tumorigenesis represents the progressive loss of original cell identity and increases in neural stemness; and (4) neural induction promotes body axis formation during embryogenesis (and ectopic neural induction causes a conjoined twin), whereas a neural induction-like process promotes tumorigenesis in postnatal animals/humans.

This Special Issue aims to address the contribution of the intrinsic neural properties or neural factors of cancer cells to the initiation and progression of cancer. This includes the promotion of cancer cell traits; the contribution of neural stemness to the phenotypic heterogeneity of tumors; and studies addressing the potential value of targeting neural stemness in cancer therapy.

Guest Editor

Prof. Dr. Ying Cao

Model Animal Research Center, School of Medicine, Nanjing University, Nanjing, China

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/247233

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).